What is VYGR's market cap?

$115.23M, based on the Nov 4 close of $1.87.

Does Voyager Therapeutics pay a dividend?

No regular cash dividend has been paid in the last year.

How much of VYGR is sold short?

3.6M shares, 7.8% of float, as of Oct 15, 2026.

What sector is VYGR in?

Healthcare, in the Biotechnology industry.

NASDAQ · VYGRHealthcareBiotechnology

Voyager Therapeutics, Inc. Common Stock (VYGR)

$1.87+2.19%

Close Nov 4, 2026 · split-adjusted

Nov 3, 2026$1.83▼ 60.13% in range

Nov 3, 2025Low $1.72 · High $5.00Nov 3, 2026

What changed · written from our data

As of Nov 4, 2026

Voyager Therapeutics closed at $1.87 on Nov 4, up 2.19%, 62.6% below its 52-week closing high. Volume of 809.4K shares was 0.80× its 20-day average (below normal).

Split-adjusted performance: -24.0% over one month, -55.2% over six months, -59.3% over one year.

In the quarter ended Jun 30, 2026, revenue was $3.17M, down 39.1% from a year earlier, with a net margin of -773.2%.

Short interest was 3.6M shares at the Oct 15 settlement, down 8.4% from the prior report (7.8% of float, 4.0 days to cover).

Market cap$115.2M61.6M shares

Revenue · quarter$3.2M−39.1% YoY

Diluted EPS$-0.40—

P/E · TTM—P/S 3.3×

Net margin-773.2%Gross 100.0%

Dividend yieldNone

52-week range1.72 – 5.00−62.6% from high

Volume809.4K0.80× 20-day avg

Volatility · 60d61.1%Annualised

Short % of float7.8%4.0 days to cover

Net cash$116.3MCash $116.3M

Next earnings—Not scheduled

Split-adjusted performance

1W +1.6%1M −24.0%3M −40.3%6M −55.2%YTD −52.4%1Y −59.3%3Y −71.4%5Y −50.0%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Biotechnology

Percentile among 139 companies (100 = best)

6-month momentum23

Revenue growth28

Net margin33

Value (low P/E)—

Size36

Industry medians: 6-month return −19.2%, revenue growth +8.8%, net margin −312.9%, P/E 22.0×.

Short interest

Details →

Shares short3.6M−8.4% vs prior

Days to cover4.0Settled Oct 15

% of float7.8%

Short vol. 10d59.4%of daily volume

Closest peers by size in Biotechnology

Company	Price	Today	6M	Rev. growth	Net margin	P/E	Mkt cap
VYGRVoyager Therapeutics	$1.87	+2.19%	−55.2%	−39.1%	−773.2%	—	$115.2M
ENGNenGene Therapeutics	$1.72	+6.17%	−80.6%	—	—	—	$115.3M	Compare
ARMPArmata Pharmaceuticals	$3.14	+1.62%	−65.3%	+15.7%	2953.8%	—	$116.8M	Compare
AVXLAnavex Life Sciences	$1.26	+5.00%	−62.3%	—	—	—	$116.8M	Compare
OTLKOutlook Therapeutics	$0.4621	+0.46%	+99.4%	−99.4%	−233554.9%	—	$112.5M	Compare
BDTXBlack Diamond Therapeutics	$1.90	+4.97%	−32.6%	—	—	—	$109.2M	Compare
LENZLENZ Therapeutics	$3.46	−1.14%	−64.3%	+9.7%	−581.8%	—	$108.7M	Compare
NMRANeumora Therapeutics	$0.5660	−0.86%	−75.7%	—	—	—	$106.3M	Compare
HUMAHumacyte	$0.4500	+2.16%	−54.2%	+34.9%	−9064.5%	—	$125.0M	Compare

News about Voyager Therapeutics

All news →

No recent articles focused on Voyager Therapeutics. 1 articles mention it in passing.

Quick answers

What does Voyager Therapeutics do?: Voyager Therapeutics Inc is a biotechnology company to leverage the power of human genetics to modify the course of and ultimately cure neurological diseases. Its pipeline includes programs for Alzheimer's disease, or AD; Friedreich's ataxia, or FA; Parkinson's disease, or PD; and multiple other diseases of the central nervous system, or CNS.
What is VYGR's market cap?: $115.23M, based on the Nov 4 close of $1.87.
Does Voyager Therapeutics pay a dividend?: No regular cash dividend has been paid in the last year.
How much of VYGR is sold short?: 3.6M shares, 7.8% of float, as of Oct 15, 2026.
What sector is VYGR in?: Healthcare, in the Biotechnology industry.

About Voyager Therapeutics

Voyager Therapeutics Inc is a biotechnology company to leverage the power of human genetics to modify the course of and ultimately cure neurological diseases. Its pipeline includes programs for Alzheimer's disease, or AD; Friedreich's ataxia, or FA; Parkinson's disease, or PD; and multiple other diseases of the central nervous system, or CNS. Many of its programs are derived from its TRACER (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) adeno-associated virus, or AAV, capsid discovery platform, which the company has used to generate novel capsids, or TRACER Capsids, and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous, or IV, dosing. Its segment is developing and commercializing genetic medicine.

HQ: Lexington, MA141 employeesListed Nov 11, 2015voyagertherapeutics.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology